MFN2 and metabolic dysfunction-associated steatotic liver disease: showed a reduction in Mfn2 expression in liver tissues of patients with nonalcoholic fatty liver disease and in mouse models.[47] Astrocyte‐specific conditional deletion of Mfn2 suppressed perivascular mitochondrial clustering and disrupted mitochondria‐ ER contact sites.[48] Our study suggest that PA treatment impairs lipid transport in MAMs, leading to lipid accumulation in USMCs, decreased lipids available for β‐oxidation, reduced ATP production, and impaired uterine contractions.